← Eichor
Study identifier: NCT06629584 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Condition: Malignant Solid Tumors  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Ghayas Issa, MD  ·  (713) 745-6798  ·  gcissa@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06629584